No Data
Beijing Beilu Pharmaceutical (300016.SZ): Renewed the concerted action agreement.
On December 16, Glonghui reported that Beijing Beilu Pharmaceutical (300016.SZ) announced that the company has recently renewed the "Joint Action Agreement" with Ms. Zeng Chunhui, the second largest Shareholder of Haichang Pharmaceutical. This renewal of the "Joint Action Agreement" has not led to a change in the actual control of Haichang Pharmaceutical, and the controlling Shareholder of Haichang Pharmaceutical remains the company. The renewal of the "Joint Action Agreement" is beneficial for the company to maintain the stability of the actual control of its holding subsidiary Haichang Pharmaceutical, ensuring consistency in major decision-making matters at Haichang Pharmaceutical, and is favorable for the coherence and stability of the company's Global Strategy and Operations management, and will not have an impact on the daily operations management of the company and Haichang Pharmaceutical.
Express News | The opening of the tenth batch of national Pharmaceutical centralized purchasing has prompted nearly 30 listed companies to announce their products are likely to be selected after the market close.
Express News | Beijing Beilu Pharmaceutical: Gadoteric acid injection solution is expected to win the bid for the tenth batch of national centralized pharmaceutical procurement.
Express News | beijing beilu pharmaceutical: The contrast agent production line has passed the EU GMP certification.
Hokuriku Pharmaceutical: Third quarter report 2024
Express News | Beijing Beilu Pharmaceutical: Net income increased by 1156% year-on-year in the first three quarters.
